If you have been reading about AOD9604 and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Last reviewed on 2025-08-19. Where a claim depends on a specific study, the study is described rather than over-claimed.
AOD-9604 is listed as a prohibited substance in sport by the World Anti-Doping Agency. It falls under the peptide hormones, growth factors, related substances, and mimetics class on the prohibited list. Anti-doping organizations treat its presence in an athlete's sample as an adverse finding unless a therapeutic use exemption applies. The prohibition reflects concerns about performance enhancement in competitive settings and the difficulty of distinguishing exogenous peptide use from endogenous hormone fragments.
Detection of AOD-9604 in biological samples relies on analytical techniques capable of distinguishing a small synthetic peptide from related endogenous sequences. Liquid chromatography coupled with tandem mass spectrometry is commonly used for confirmatory analysis. Sample preparation may involve immunoaffinity enrichment or solid-phase extraction to concentrate the peptide. Because the molecule is small and may be present at low concentrations, assay sensitivity and specificity are ongoing analytical challenges. Laboratories also validate methods against reference materials when available.
Regulatory interest in AOD-9604 increased after high-profile anti-doping cases involving peptide products. In some cases, the substance was supplied under alternative names or in compounded preparations, complicating traceability. Sports tribunals and anti-doping panels have discussed whether the peptide was explicitly banned at the time of use, leading to clarifications by the World Anti-Doping Agency. For consumers and researchers, the legal status can vary by jurisdiction, and products marketed as research chemicals may lack independent quality verification.
AOD-9604 drew attention in the 1990s and 2000s as a potential anti-obesity agent. Early work explored both injectable and oral routes, which is unusual for a peptide of this size. Animal studies reported changes in fat metabolism without the growth-promoting or insulin-like effects associated with full-length growth hormone. Subsequent human trials produced mixed or modest results, and the compound did not obtain regulatory approval for weight management in major markets. It remains known mainly through research literature, sports anti-doping listings, and non-approved supplement advertising.
AOD-9604 is prohibited in sport by the World Anti-Doping Agency under the peptide hormone class. Its presence in a sample can be detected through mass spectrometry-based methods, although the exact assay depends on the laboratory. In research settings, material is often supplied as a lyophilized powder for reconstitution. Buyers and researchers should note that products labeled AOD-9604 may vary in purity and actual peptide content. Analytical certificates and independent testing are common ways to verify identity, but no global harmonized standard exists for all commercial lots.
| Property | Value | Notes |
|---|---|---|
| Regulatory status | Prohibited in sport | Listed by WADA under peptide hormones |
| WADA class | S2 | Peptide hormones, growth factors, related substances, and mimetics |
| Approved therapeutic use | Not established | Clinical research did not lead to broad marketing approval |
| Common detection method | LC-MS/MS | Liquid chromatography-tandem mass spectrometry |
| Sample preparation | Extraction and enrichment | Immunoaffinity or solid-phase extraction may be used |
Research interest in AOD-9604 often focuses on whether it can influence lipid metabolism without the growth-promoting or glucose-related effects of full-length hGH. This question remains unresolved, and findings depend on model, dose, and measurement method. Some reviews treat the peptide as a historical obesity candidate rather than an active therapeutic. Others cite it in discussions of peptide fragments, metabolic signaling, and performance-enhancing substances. Clear conclusions are limited by the small number of rigorous, independent human studies.
AOD-9604 has been investigated primarily as a potential treatment for obesity and related metabolic conditions. Early laboratory work examined its effects on fat cells, and later studies moved into animal models and human clinical trials. Some trials reportedly reached Phase II, but the program did not lead to an approved medicine. Published summaries often note that weight-loss results were modest or inconsistent. The full trial data are not all publicly available in detail.
Regulatory treatment of AOD-9604 has varied. In sports anti-doping, the peptide became widely discussed during a 2013 investigation into an Australian professional sports club. Authorities at the time debated whether it fell under prohibitions on growth hormone and related substances. Later clarifications and updated lists have addressed the compound in different ways. Anyone seeking current status should consult the latest applicable rules, and commercial supply for human use is not authorized in major markets.
Clinical development of AOD9604 included trials in people with obesity, but the results did not lead to approval as a prescription medicine in major markets. Interest later shifted to research settings and to unapproved products marketed for body composition. Regulatory agencies have questioned whether the peptide qualifies as a dietary ingredient, and some have issued warnings about its presence in supplements. Long-term human safety data are limited, and questions about efficacy, dosing, and target populations remain unresolved.
AOD9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to a short sequence near the end of the 191-amino-acid hormone, often described as residues 176–191 or a related fragment. Researchers designed it to separate metabolic effects from the growth-promoting actions of full-length growth hormone. Early work in the 1990s explored it as a candidate for weight and lipid disorders. It is not a naturally circulating hormone fragment produced in large amounts.
Stability of AOD-9604 depends on storage conditions. Lyophilized powder is generally more stable than reconstituted solution. Recommended storage is typically at -20°C or lower, protected from light and moisture. Repeated freeze-thaw cycles can cause aggregation or degradation. In solution, the peptide may be susceptible to hydrolysis or oxidation, so aliquoting and cold storage are common practices. Researchers often add stabilizers such as mannitol or trehalose during lyophilization to improve shelf life.
Quality control for AOD-9604 involves verifying identity, purity, and concentration. Suppliers may provide a certificate of analysis listing HPLC purity and mass spectrometry data. Independent verification is advised because peptide products can vary in quality. Researchers should check for counterions, residual solvents, and microbial contamination. Proper documentation supports reproducibility and safety in laboratory studies. When sourcing, institutions often require third-party testing and detailed chain-of-custody records. These steps help ensure that experimental results are attributable to the peptide rather than impurities.
Analytical characterization of AOD-9604 typically employs reversed-phase high-performance liquid chromatography (RP-HPLC) to assess purity and identity. Mass spectrometry provides confirmation of molecular mass, while amino acid analysis can verify composition. These methods are standard for peptide research chemicals. Because the peptide lacks a distinct chromophore, detection often relies on ultraviolet absorbance at 214 nm or mass spectrometric response. Laboratories may also use capillary electrophoresis for separation. For example, size-exclusion chromatography can detect aggregates.
A study on the age of the carbonate thin layers covering or underlying rock art from the Cave of Altamira (Spain), providing evidence of several periods of cave art from the ceiling of the studied cave, is published by Pons-Branchu et al. (2026). Evidence from the Velika Pećina, Velika Vranovica and Pećina kod Stene cave sites (Serbia), indicative of human presence in central Balkans during the Last Glacial Maximum, is presented by Kuhn et al. (2026). Masojć et al. (2026) describe a Late Pleistocene human tooth from the Khutul Usny Cave site, representing the first fossil of an early Homo sapiens in Mongolia with secure geological context and providing evidence of presence of the species in southern Mongolia around the onset of the Last Glacial Maximum. A study on the frontal and mandibular morphology of the Red Deer Cave people, interpreted as consistent of affinities with Homo sapiens and indicative of diversity cranial morphology of late Pleistocene hominins from eastern Asia, is published by Fan et al. (2026). Evidence indicating that Solutrean artifacts from the Peña Capón rock shelter (Muriel-Tamajón, Spain) were sourced 600 to 700 kilometers away from this site, in the present-day territory of southwest France, is presented by Sánchez de la Torre et al. (2026). Nash et al. (2026) report rediscovery of putative Upper Paleolithic cave art from the Bacon Hole site (Wales, United Kingdom) originally discovered by William Sollas and Henri Breuil in 1912 and support the interpretation of the studied horizontal lines as cave art. Reiche et al.
=== Mood disorders === In the case of mood disorders, specifically bipolar disorder, it is hypothesized that N-acetyl-cysteine (NAC), acetyl-L-carnitine (ALCAR), S-adenosylmethionine (SAMe), coenzyme Q10 (CoQ10), alpha-lipoic acid (ALA), creatine monohydrate (CM), and melatonin could be potential treatment options.
For services to the Care of Wildlife in Northumberland. Walter Wilson Ross, Conductor, Pension Silver Band, East Lothian. For services to Music. Charles Routledge, Dresser. For services to the Theatre. David Walton Routledge. For services to the community in Hillingdon, Middlesex. Harold Rowling. For services to the community in Westmeston, East Sussex. Shantilal Hirji Ruparell. For services to the community in Harrow, Middlesex. James Edwin Rous Saltonstall. For services to Yachting and to Young People. Anne Mary Sankaran. For services to the community in Oldham, Lancashire. Peter Saunders, Chairman, Groundwork Trust, Merthyr and Cynon. For services to the Environment. Alan Digerson Savage. For services to the Croydon Battle of Britain Memorial and to the Royal Air Force Benevolent Fund. John Robert Savage. For services to the community in Southwell, Nottinghamshire. Leslie Daniel Sayer, . For services to the Telegraphist Air Gunners' Association. Barry Scaplehorn, lately Firefighter, Suffolk County Fire Service. For services to the Fire Services Benevolent Fund. Susan Scarsbrook, Head, Sudbourne Primary School, Lambeth, London. For services to Education. David Andrew Seaman. For services to Association Football. Peter Jonathan Seaman, lately Chief Inspector, Hertfordshire Constabulary. For services to the Police. Sukumar Sen. For services to the community in Lochaber. Dorothy Sewell. For services to the community in Middlesbrough, North Yorkshire. Robert James Shaw. For services to the Fishing Industry. Patrick John Sherwin. For services to Coastal Rowing.
=== Civil rights === Bhutto Zardari has repeatedly defended the rights of minorities in Pakistan. On 4 December 2012, in a statement responding to reports about the demolition of a Hindu temple in Karachi and a desecration of an Ahmadiyya graveyard in Lahore he said, "Our forefathers did not sacrifice their lives for an intolerant, extremist, sectarian, and authoritarian Pakistan. I appeal to all of you to rise up and defend Jinnah's Pakistan. My party and I will stand by you, shoulder to shoulder." During a cake cutting ceremony for Christmas in Karachi, on 25 December 2018, Bhutto Zardari said that he PPP is the custodian of social justice, parity, religious, and interfaith harmony in the country and its advocacy for the prevalence of peace and tranquility across the world is heavily established. At the memorial for the 7th death anniversary of former Federal Minister of Interfaith Harmony, Shahbaz Bhatti on 3 March 2018, Bhutto Zardari said, "May I take this opportunity to say that we share the concerns over the misuse of blasphemy laws. This is the concern of not only the Christian community but of all of us. It is my concern too. These laws have been used as a tool by extremists to settle personal scores. They have been used to grab the properties of Christians and other non-Muslims. The blasphemy laws carry the mandatory death penalty. We must prevent their misuse. We will." On 29 September 2019, he visited the Hindus in Ghotki and the Sacho Satram Dham temple which was desecrated in the 2019 Ghotki riots and condemned the attack.
Sources: en.wikipedia.org
The most northerly black smokers are a cluster of five named Loki's Castle, discovered in 2008 by scientists from the University of Bergen at 73°N, on the Mid-Atlantic Ridge between Greenland and Norway. These black smokers are of interest as they are in a more stable area of the Earth's crust, where tectonic forces are less and consequently fields of hydrothermal vents are less common. The world's deepest known black smokers are located in the Cayman Trough, 5,000 m (3.1 miles) below the ocean's surface.
== Structure and binding == HLA-DM contains a N-terminal class II histocompatibility antigen, alpha domain and a C-terminal Immunoglobulin C1-set domain. Research in crystallography has resulted in advanced knowledge on HLA-DM structure, and how it binds to its substrates (HLA-DO and MHC class II molecules).
Nervous tissue is composed of many nerve cells known as neurons which transmit information. In some slow-moving radially symmetrical marine animals such as ctenophores and cnidarians (including sea anemones and jellyfish), the nerves form a nerve net, but in most animals they are organized longitudinally into bundles. In simple animals, receptor neurons in the body wall cause a local reaction to a stimulus. In more complex animals, specialized receptor cells such as chemoreceptors and photoreceptors are found in groups and send messages along neural networks to other parts of the organism. Neurons can be connected together in ganglia. In higher animals, specialized receptors are the basis of sense organs and there is a central nervous system (brain and spinal cord) and a peripheral nervous system. The latter consists of sensory nerves that transmit information from sense organs and motor nerves that influence target organs. The peripheral nervous system is divided into the somatic nervous system which conveys sensation and controls voluntary muscle, and the autonomic nervous system which involuntarily controls smooth muscle, certain glands and internal organs, including the stomach.
=== Caffeine === One tablespoonful (5 grams) of dry unsweetened cocoa powder has 12.1 mg of caffeine and a 25-g single serving of dark chocolate has 22.4 mg of caffeine. This is much less than the amount found in coffee, of which a single 7 oz. (200 ml) serving may contain 80–175 mg of caffeine, though studies have shown psychoactive effects in caffeine doses as low as 9 mg, and a dose as low as 12.5 mg was shown to have effects on cognitive performance.
=== Imaging === Mammography is the method of choice for radiologic examination of male breast tissue in the diagnosis of gynecomastia when breast cancer is suspected on physical examination. If a mass/lump is felt during a physical exam, some features of the lump that would point to malignancy would be painless, non-movable (fixed), irregularly shaped, and skin changes. Mammography is rarely indicated for men since breast cancer is an unlikely diagnosis. If mammography is performed and does not reveal findings suggestive of breast cancer, further imaging is not typically necessary. If a tumor of the adrenal glands or the testes is thought to be responsible for the gynecomastia, ultrasound examination of these structures may be performed.
Sources: en.wikipedia.org
Yes, the World Anti-Doping Agency classifies AOD-9604 as a prohibited peptide hormone and related substance. Its use by athletes is banned under the relevant anti-doping code.
Confirmatory detection typically uses liquid chromatography with mass spectrometry. Immunoassays may be used for screening, but mass spectrometry provides structural confirmation.
No widely approved therapeutic indication exists for AOD-9604. It has been investigated in clinical studies, but regulatory approvals for general medical use are not established.
No. It is a synthetic peptide fragment modeled on part of human growth hormone, not the full hormone. It does not contain the complete sequence or receptor-binding regions of hGH.